Rosai–Dorfman disease (RDD) is a rare non-Langerhans cell histiocytosis that was first described as sinus histiocytosis with massive lymphadenopathy by Rosai and Dorfman in 1969. While classical/nodal RDD is typical, extranodal involvement is seen in up to 43% of all cases, with 23% showing only extranodal lesions. Here, we present a case of disseminated extranodal RDD, where the initial symptoms were cutaneous manifestations.
We report a pediatric patient with acquired cold urticaria who developed a systemic reaction triggered by localized cold exposure. By determining the critical threshold temperature using TempTest®, we were able to minimize restriction in activities.
A 57-year-old woman who was inoculated with the second dose of the mRNA-1273 Moderna COVID-19 vaccine and then developed adult-onset still’s disease as a result.
This was the first case report in which an in-class IL-23 p19 inhibitor was switched (from guselkumab to tildrakizumab) during psoriasis vulgaris treatment. Four months after the switch, genital lesions, which were the patient's most significant complaint, improved with no subsequent worsening. We believe that our case will aid physicians who work in this problematic clinical setting.
Dupilumab treatment reduced serum SCCA2 levels in patients with atopic dermatitis. Interestingly, even though the skin eruptions had not yet fully disappeared, serum SCCA2 levels were reduced well to below normal by the administration of dupilumab.
We report a rare case of granulomatosis with polyangiitis (GPA) who presented with relapsing erythema nodosum (EN)-like eruption as a solo vasculitis-associated cutaneous manifestation. We suggest that EN-like eruption alone can be a cutaneous symptom of GPA if subcutaneous medium-sized vessels are exclusively affected.
Dupilumab has been deemed highly effective for atopic dermatitis (AD). However, there have been no reports performing a combination analysis with hematological data and improvement rates pertaining to the continued use of dupilumab for up to 2 years in real world. In this study, we evaluated the effectiveness and safety of using dupilumab for up to 2 years in 9 patients with AD at our hospital.
Thirty-six patients with moderate-to-severe AD treated by dupilumab, and 9 of them treated for 2 years. Changes in the severity scoring, pruritus numerical rating scale (NRS), patient-oriented eczema measure (POEM), serum levels of immunoglobulin E (IgE), thymus and activation-regulated chemokine (TARC), eosinophils, and lactate dehydrogenase (LDH) at Week 0, 2, 4, 16, 48, 72, and 96 of those patients were investigated, and we studied features of the patients who had any adverse events (AEs).
Investigator’s global assessment (IGA), eczema area and severity index (EASI), body surface area (BSA), NRS, POEM, and serum levels of LDH were significantly decreased from Week 4 onwards to Week 96 compared with baseline condition. Serum levels of TARC and LDH were significantly decreased from Week 4 onwards to Week 96. Regarding 9 patients who were treated with dupilumab for up to 2 years, serum levels of TARC and eosinophils decreased without statistical significance. The serum levels of IgE significantly decreased at Week 72, 96 compared with the baseline. Regarding as AEs, ocular symptoms were the most frequently observed (15/36, 41.2%), and there were no cases of discontinuation due to AEs.
Treatment with dupilumab was well tolerated and showed improvements in AD for at least 2 years.
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：